Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Camrelizumab + Palbociclib for Resectable ESCC
NCT07191977Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, palbociclib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by West China Hospital of Sichuan University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
camrelizumabpalbociclib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07191977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191977.